Loading
Tigilanol tiglate (Stelfonta) is an injection into the tumour, approved by the US Food and Drug Administration in 2020 to treat mast cell tumours in dogs. In people it is still experimental and is being tested in sarcoma and head and neck cancer.
Stelfonta (tigilanol tiglate injection) was approved by the FDA Center for Veterinary Medicine on 16 November 2020 under NADA 141-541, sponsored by QBiotics Group Ltd, for use in dogs for the treatment of non-metastatic cutaneous mast cell tumors and non-metastatic subcutaneous mast cell tumors located at or distal to the elbow or the hock. The FDA described it as the first approval of an intratumoral injection for non-metastatic mast cell tumours in dogs. It must be given with a corticosteroid and H1 and H2 receptor blockers to reduce the risk of systemic reactions from mast cell degranulation.
In the field study, 60 of 80 treated dogs (75%) had a complete response at day 28, against 2 of 38 untreated controls (5.3%); 8 of 18 dogs retreated at day 30 had a complete response four weeks later. In people, QBiotics is running phase 2 trials of intratumoural tigilanol tiglate in soft tissue sarcoma (NCT05755113) and head and neck cancer (NCT05608876); two melanoma trials (NCT04834973 with pembrolizumab, NCT05234437) were terminated.
Injected into the tumour, it lyses cells and activates a protein kinase C (PKC) cascade that spreads through the treated tumour, causing an acute inflammatory response and increased permeability of the tumour blood vessels that leads to their destruction; the FDA summary notes it does not specifically target cancer cells. Connects to Protein kinase C family (PKC).
1.The drug is injected directly into the tumour
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Tigilanol tiglate" OR ABSTRACT:"Tigilanol tiglate" OR TITLE:"Stelfonta" OR ABSTRACT:"Stelfonta" OR TITLE:"EBC-46" OR ABSTRACT:"EBC-46" OR TITLE:"tigilanol tiglate injection" OR ABSTRACT:"tigilanol tiglate injection") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tigilanol tiglate, not a curated reading list.
Shares Veterinary and comparative oncology, Pet dogs with spontaneous cancer as a bridge before human trials and the tags veterinary, comparative-oncology.
Shares Veterinary and comparative oncology, Pet dogs with spontaneous cancer as a bridge before human trials and the tags veterinary, comparative-oncology.
Shares Veterinary and comparative oncology, Pet dogs with spontaneous cancer as a bridge before human trials and the tags veterinary, comparative-oncology.
Shares Veterinary and comparative oncology, Pet dogs with spontaneous cancer as a bridge before human trials and the tags veterinary, comparative-oncology.
Shares the tags veterinary, comparative-oncology.
Shares the tags veterinary, comparative-oncology.
Shares the tags veterinary, comparative-oncology.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/